Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder

Treatments: Drug: Comparator: paroxetine HCL; Drug: MK0869, aprepitant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00035009

MK0869-059

2006_402

Formally-1A407

0869-059

Details and patient eligibility

About

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Full description

The duration of treatment is 8 weeks.

Enrollment: 468 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Major Depressive Disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind